. Loss of heterozygosity of 3p14 loci is also frequently observed in normal or metaplastic bronchial epithelium in smokers and ex-smokers (Mao et al, 1997) .
The cellular targets for the carcinogenic compounds of tobacco smoke are usually considered to be either the bronchial mucosa or alveolar epithelium (Carney, 1991) . In a previous study, testing the hypothesis of the presence of widespread target cells containing K-ras mutations in the respiratory tract, we did not find any mutation of codon 12 of the K-ras gene in non-neoplastic distal bronchial or parenchymal tissues in patients with lung adenocarcinoma (Urban et al, 1996) . Similarly, in a recent report comparing neoplastic tissue and contralateral bronchial mucosa, the authors failed to detect K-ras mutations in non-neoplastic cells (Behn et al, 1998) . In contrast, Clements et al (1995) reported K-ras mutations in non-malignant bronchial tissue in some patients with lung adenocarcinomas.
Bronchial carinae are the main sites of impaction of airborne contaminants such as tobacco smoke compounds (Knudson, 1960; Auerbach et al, 1979) . It can be hypothesized that these areas may constitute targets for the genotoxic effects induced by carcinogenic compounds, such as K-ras gene mutations. As a preliminary step to test this hypothesis, we therefore investigated the occurrence of K-ras mutations in non-neoplastic bronchial carinae from a series of patients with lung adenocarcinomas with and without K-ras mutations. The study was performed on non-neoplastic bronchial carinae collected from lungs after thoracotomy for primary lung adenocarcinomas in 19 patients.
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MATERIALS AND METHODS

Tissue specimens
Lung specimens from 19 patients with lung adenocarcinomas were evaluated (Tables 1 and 2 ). All patients underwent preoperative staging and bronchoscopy with serial carinal biopsies for histological staging as a routine procedure. All but one (patient 13) of the patients were smokers or ex-smokers. All tissue samples investigated in the present study were collected from specimens obtained after thoracotomy performed for curative intent with a curative resection, i.e. lobectomy or pneumonectomy. This study was therefore conducted in accordance with the rules of the Ethical Committee of our institution.
The resected lung was rapidly transported to the Pathology Department. After examination by the pathologist, non-neoplastic bronchial carina specimens away from the primary tumour, either from the same lobe in the case of lobectomy (n = 14) or if possible from another lobe in the case of pneumonectomy (n = 5), were collected and snap-frozen at -70°C until analysis. The standard bronchial nomenclature was used to localize the tumour and carinae (Kitamura and Kobayashi, 1995) . Only specimens from lungs containing a tumour situated away from the non-neoplastic carina were sampled. A representative part of the tumour was also snap-frozen and stored at -70°C until analysis. Tissue samples were embedded in paraffin wax for histological analysis and classified according to the WHO classification into adenocarcinomas. To increase the sensitivity of our method of detection of codon 12 K-ras mutations, macroscopically neoplastic tissue and bronchial carina were studied under a dissection microscope for DNA extraction.
Control cell lines
HT29 (homozygous for the wild K-ras gene codon 12, glycine, GGT) and SW480 (homozygous for a mutated K-ras gene codon 12, valine, GTT) human colon carcinoma cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Tumour DNA with pre-determined codon 12 mutations identified by sequencing was also used as control DNA.
Enriched PCR/RFLP analysis
K-ras codon 12 sequences were amplified (Perkin-Elmer Cetus thermal cycler) by an enriched polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method, as previously reported (Kahn et al, 1991; Urban et al, 1996) .
First-step amplification
The first PCR reaction used a K-ras 5′ primer (5′ ACT GAA TAT AAA CTT GTG GTA GTT GGA CCT 3′) containing a C substitution at the first position of codon 11 creating a BstNI site which overlaps the first two nucleotides of codon 12, and K-ras 3′ widetype (wt) primer (5 TCA AAG AAT GGT CCT GCA CC 3′) (part of exon 1 of K-ras gene). Fifteen cycles of a PCR reaction were performed with an annealing temperature of 56°C with the following reagents: 50 mM potassium chloride, 10 mM Tris-HCl pH 8.3, 1.5 mM magnesium chloride, 0.2 mM dNTPs, 2.5 units of Taq DNA polymerase (Boehringer Mannheim, France), and 10 ng each of K-ras 5′ and K-ras 3′ wt primers.
Intermediate digestion
Five-microlitre aliquots of the first PCR reaction were digested with 10 units of the restriction enzyme BstNI (Boehringer Mannheim, France) in a final volume of 10 µl, at 37°C for 1 h under conditions recommended by the supplier.
Second-step amplification
One microlitre of digested mixture was diluted to a final volume of 50 µl as described above. Primer concentrations were 150 ng each of K-ras 5′ (as described above) and K-ras 3′ primers (5′ TCA AAG AAT GGT CCT GGA CC3′), which also contain a substitution creating a control BstNI site. Amplification was performed for 30 cycles, as described above. Thirty-microlitre aliquots obtained after this second step were snap-frozen at -30°C for further analysis.
RFLP analysis
Twenty-microlitre aliquots of the PCR products obtained after the second step were digested with 10 units of the restriction enzyme BstNI, at 37°C for 2 h in a final volume of 40 µl. The results were analysed by 8% polyacrylamide electrophoresis followed by ethidium bromide staining and UV transillumination. All specimens were re-evaluated in a second separate PCR amplification.
Codon 12 sequences
Nucleotide sequences of ten mutated K-ras codon 12 detected after enriched PCR/RFLP analysis were determined by either a Genetic Analyser or specific oligonucleotide hybridization according to Hruban et al (1993) . Twenty samples without K-ras mutation were also sequenced as controls. Sequencing was performed with purified PCR/RFLP products obtained immediately after the second PCR amplification step (as described above) without second BstNI reaction. Cycle sequencing was performed using the ABI PRISM™ dRhodamine Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq® DNA polymerase FS (Applied Biosystems, Paris) in a GeneAmp PCR systems 9600 (Perkin-Elmer). The precipitated pellets were resuspended in Template Suppression Reagent® (Applied Biosystems, Paris, France), denatured and electrophoresed on the ABI Prism 310 Genetic Analyser. The PCR product sequence was analysed with ABI PRISM™ software.
Oligonucleotide sequences, hybridization conditions in ammonium tetramethylchloride, specific washing conditions and composition of the probes used have been previously described by Wilentz et al (1998) .
RESULTS
Patients
Nineteen patients with lung adenocarcinomas were studied. Nonneoplastic bronchial carina samples were available in all 19 patients, as reported in Tables 1 and 2 . Surgical resection consisted of lobectomy (n = 14) or pneumonectomy (n = 5). Eight patients presented an endobronchial tumour diagnosed during a bronchoscopy procedure, whereas 11 patients had a peripheral lung tumour, mainly in a subpleural site. The tumours were classified according to the TNM classification as stage I (11/19), stage II (2/19), stage III (4/19) or stage IV (2/19). Two patients were classified as stage IV because of isolated cranial metastasis and underwent complete neurosurgical resection. Enriched PCR/RFLP method SW480 and HT29 human colon carcinoma cell lines were used to validate our PCR/RFLP method. Amplification of the K-ras codon 12 sequence gave a 157 bp fragment before BstNI digestion. After the two-step procedure described above, digestion of wild-type codon 12 sequence (HT29 cell line DNA) with BstNI generated a 114 bp fragment, while, when a mutation was present in codon 12 (SW480 cell line DNA), BstNI digestion generated a 143 bp fragment, as shown in Figure 1 . The presence of a 143 bp fragment after digestion is therefore the hallmark of the presence of mutated K-ras genes on codon 12. Analysis of a mixture of DNA from the two cell lines showed two fragments of 143 and 114 bp respectively. The sensitivity of the assay was therefore controlled by a series of titration experiments. The limit of detection was 1 cell with homozygous mutation within a minimum of 10 3 cells with a wild-type K-ras gene, as previously reported (Urban et al, 1996) .
Detection of codon 12 c-K-ras mutations in patient samples
The detailed results are shown in Tables 1 and 2 . A mutation in codon 12 of the K-ras gene was observed in eight of the 19 lung adenocarcinomas (42%) (Tables 1 and 2) . A mutation in codon 12 of the K-ras gene was observed in nine of the 41 non neoplastic bronchial carina samples evaluated (22%), i.e. in six of the 19 patients (32%) (Tables 1 and 2 ).
Lung tumour and non-neoplastic carinae
Four different patterns were observed, expressed as groups 1, 2, 3 and 4 (Tables 1 and 2 ).
In group 1: (patients 1-4), a K-ras mutation was detected in lung tumours, but not in bronchial carinae (Table 1) .
In group 2: (patients 5-8), K-ras mutations were detected in lung tumours and in bronchial carina samples collected away from the tumour. It must be stressed that, for patient 6, presenting a tumour located in the right upper lobe, no mutation was detected in the upper lobe carina, but a K-ras gene mutation was detected in the apical carina of the right lower lobe (Table 1) .
In group 3: (patients 9 and 10), no mutation was detected in the tumours of these two patients, despite multiple (n = 3) evaluation by enriched PCR/RFLP, but mutations were present in bronchial carinae (Table 2) .
In group 4: (patients 11-19), no mutation was detected in either lung tumour or bronchial carina samples (Table 2) .
Codon 12 sequences
Detailed data are reported in Table 2 . The type of codon 12 K-ras mutations was always G to T transversions, TGT and GTT, in both carina and lung tumours (Figure 2 ).
DISCUSSION
The method used to detect mutation in the 12th codon of the K-ras gene was a combination of PCR DNA amplification and RFLP analysis (Jiang et al, 1989; Urban et al, 1993) . This method is highly specific, as loss of the restriction site at the target is diagnostic for the presence of a mutation (Jiang et al, 1991; Urban et al, 1996; Behn et al, 1998) . The enriched PCR/RFLP procedure is able to detect one mutated allele among 10 3 normal alleles, while a one-step PCR/RFLP analysis is only able to detect a K-ras mutation present in 1% of cells studied (Urban et al, 1996) . Used as a control of this method, specific oligonucleotide hybridization gave similar results in previously published experiments (Urban et al, 1996) .
In the present series of 19 lung adenocarcinomas, activated protooncogene K-ras by mutation on codon 12 was observed in eight lung adenocarcinomas (42%), as already reported previously (Rodenhuis et al, 1988; Slebos et al, 1990; Urban et al, 1996) . However, similar results have been recently reported; for example Ronai et al (1996) detected K-ras mutation in 48% of a series of non-small-cell lung carcinomas.
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British Journal of Cancer (2000) K-ras mutation has been shown to be a preneoplastic event in colonic and pancreatic carcinogenesis (Burmer and Loeb, 1989; Yanagisawa et al, 1993; Berthelemy et al, 1995; Brentall et al, 1995; Tada et al, 1996; Wilentz et al, 1998) . Moreover, when using an enriched PCR method, K-ras mutations were detected in normal colonic mucosa away from the tumour (Minamoto et al, 1995) . K-ras mutations have also been detected in mucous hyperplasia of pancreatic ducts associated with pancreatitis, suggesting that they may be precancerous epithelial changes in the pathogenesis of pancreatic carcinomas (Yanagisawa et al, 1993) .
In contrast, data concerning preneoplastic events in bronchopulmonary carcinogenesis are more recent and incomplete. p53 mutations have been shown to occur very early in the development of lung adenocarcinomas (Sozzi et al, 1992; Sundaresen et al, 1992; Benett et al, 1993; Li et al, 1994) , and a linkage with tobacco smoke exposure has been clearly established with the presence of genetic abnormalities in the p53 gene (Denissenko et al, 1996) . In a recent study based on serial bronchial biopsies, Mao et al (1997) reported a high frequency of genetic abnormalities of the 3p14 loci (FHIT 3p14.2 gene) and, less frequently, of the 9p21 loci (p16 gene) and 17p13 loci (p53 gene) in normal and metaplastic bronchial epithelium sampled in smokers and non-smokers. Loss of heterozygosity of 3p14 chromosome was observed in 88% of smokers and 45% of ex-smokers, but was a very rare event in nonsmokers, and was more frequently observed in the case of a high metaplastic index. This observation suggested a linkage with tobacco smoke exposure and potential reversibility of 3p14 genetic abnormalities in ex-smokers. In contrast, the early occurrence of K-ras mutation is still controversial as for some authors it is considered as a late event in the carcinogenesis of lung tumours (Sugio et al, 1994) . However, our results as well as those previously reported by Clements et al (1995) suggest that K-ras mutation could be an earlier event than usually considered.
The cellular targets for the carcinogenic compounds of tobacco smoke are usually considered to be either the bronchial mucosa or alveolar epithelium (Carney, 1991) . The hypothesis of the presence of widespread target cells containing K-ras mutations in the respiratory tract, as already shown for the affected suppressor gene p53, therefore had to be considered (Sozzi et al, 1992; Sundaresen et al, 1992; Benett et al, 1993; Li et al, 1994) . We previously tested this hypothesis by evaluating distal tissues, i.e. non-proximal bronchial or parenchymal tissues, but failed to find any mutations on codon 12 of the K-ras gene in these tissues, in patients with lung cancers (Urban et al, 1996) . In 1995, Clements et al reported K-ras mutations in non-malignant bronchial tissues collected under fibreoptic bronchoscopic examination in patients with nonsmall-cell lung carcinomas (Clements et al, 1995) . We therefore hypothesized that such a discrepancy between these results (Li et al, 1994; Urban et al, 1996; Behn et al, 1998) could be explained by the fact that the samples studied by Clements et al were collected from proximal bronchial carinae, which are the main sites of impaction of tobacco smoke compounds, shown to be the site of epithelial changes in response to constant exposure to airborne contaminants (Knudson, 1960; Auerbach et al, 1979 ).
The present study shows that K-ras gene mutations in codon 12 can be present in non-neoplastic bronchial carina in patients with lung adenocarcinomas. These mutations were detected either away from a tumour harbouring a K-ras mutation, but also in two patients not presenting any mutation in the carcinoma, despite multiple evaluations by enriched PCR/RFLP, confirmed by sequencing analysis. This finding clearly demonstrates that the presence of mutated K-ras, at least in these three cases, was not related to a theoretical possibility of endobronchial contamination by tumour cells.
Codon 12 mutations were found to be G to T transversions, mostly TGT and GTT, in carina samples and lung tumours. These results are in accordance with previous studies (Kobayashi et al, 1990; Westra et al, 1993; Rodenhuis et al, 1997) . Benzo(a)pyrene, and nitrosamines, considered to be the major carcinogenic compounds of tobacco smoke (Loeb et al, 1984; Carothers, 1990) , have been demonstrated to induce mostly G to T transversion in experimental murine models of lung tumours harbouring a K-ras mutation restricted to codon 12 (You et al, 1989 (You et al, , 1993 Mass et al, 1993) .
The significance of K-ras activation in lung carcinogenesis therefore remains to be elucidated. One hypothesis is that such a mutation could be a marker of exposure to tobacco smoke carcinogenic compounds in patients at risk for lung adenocarcinoma. In fact, in experimental murine lung tumour models performed in F1 littermates from susceptible and resistant parents, it has been shown that codon 12 mutations affect the K-ras allele from the susceptible parent (You et al, 1992) . It has also recently been shown that K-ras polymorphism associated with two other polymorphic markers from chromosome 12p was associated with a risk of lung adenocarcinoma (Manenti et al, 1997) .
In conclusion, mutated K-ras can be detected in non-neoplastic bronchial mucosa, particularly bronchial carina, which is the main site of impaction of airborne contaminants such as tobacco smoke compounds. The results of this study now need to be confirmed by a larger study conducted in smokers and non-smokers with or without various types of lung carcinomas.
